Protective Effect of Decursinol on Mouse Models of Sepsis: Enhancement of Interleukin-10.
10.4196/kjpp.2008.12.2.79
- Author:
Jun Sub JUNG
1
;
Ji Jing YAN
;
Dong Keun SONG
Author Information
1. Department of Pharmacology, College of Medicine, Institute of Natural Medicine, IDMRC, Hallym University, Chuncheon 200-702, Korea. dksong@hallym.ac.kr
- Publication Type:Original Article
- Keywords:
Decursinol;
Experimental sepsis;
Interleukin-10
- MeSH:
Animals;
Benzopyrans;
Butyrates;
Interleukin-10;
Interleukin-12;
Interleukin-6;
Ligation;
Mice;
Plasma;
Punctures;
Sepsis;
Tumor Necrosis Factor-alpha
- From:The Korean Journal of Physiology and Pharmacology
2008;12(2):79-81
- CountryRepublic of Korea
- Language:English
-
Abstract:
The effects of decursinol on various models of sepsis were investigated. Intra-peritoneal pretreatment of mice with various doses of decursinol (1~100 mg/kg) effectively suppressed lethality induced in three mouse models of experimental sepsis, i.e., lipopolysaccharide (LPS)/D-galactosamine (GalN), high-dose LPS (20 mg/kg), and cecal ligation and puncture (CLP). Intra-peritoneal pretreatment of mice with decursinol (50 mg/kg) markedly enhanced the LPS/GalN-induced increase of plasma interleukin-10 (IL-10) levels, without affecting plasma TNF-alpha, IL-6 and IL-12 levels. These results suggest that decursinol could be effective for prevention or treatment of sepsis.
